Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. uri icon

Overview

abstract

  • Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).

publication date

  • October 28, 2010

Research

keywords

  • Abdominal Neoplasms
  • Granuloma, Plasma Cell
  • Neoplasms, Muscle Tissue
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Pyrazoles
  • Pyridines

Identity

PubMed Central ID

  • PMC3014292

Scopus Document Identifier

  • 78049428879

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1007056

PubMed ID

  • 20979472

Additional Document Info

volume

  • 363

issue

  • 18